Véronique D’Hondt

Multifactorial Approach to Predicting Resistance to Anthracyclines

Christine Desmedt, Angelo Di Leo, Evandro de Azambuja et al. · Journal of Clinical Oncology · 2011 · 187 citations

Medicine, Oncology, Pharmacology +16

Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer

Paul Cottu, Véronique D’Hondt, Sylvain Dureau et al. · Annals of Oncology · 2018 · 170 citations · Full text

Medicine, Oncology, Pharmacology +15

Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial

Amit M. Oza, Ursula A. Matulonis, Susanne Malander et al. · The Lancet Oncology · 2018 · 126 citations

Pharmacy, Gynecology, Oncology +15

Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases

William Jacot, Elvire Pons‐Tostivint, Jean‐Sébastien Frenel et al. · Breast Cancer Research and Treatment · 2016 · 118 citations

Medicine, Oncology, Breast Oncology +10

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer

Charles E. Geyer, M. Untch, Chiun‐Sheng Huang et al. · New England Journal of Medicine · 2025 · 115 citations · Full text

Medicine, Oncology, Pharmacology +14